<p>Legend: <sup>§</sup>The values of mean±SD are listed;</p>*<p>Comparison with respective controls;</p>**<p>Comparison between type 1 and type 2 patients;</p>***<p>v.n. <25 mg/L The parameters with significantly different (p<0.05) values are listed in bold.</p
<p>(a) Heat-map of fold change of 33 differential metabolites; (b) Discrimination T2DM from DACD in ...
<p>Values are mean ± SEM.</p><p>n. a., not assessed.</p>*<p>p<0.05 baseline IT vs. 10th day of IT,</...
<p>Clinical and biochemical characteristics of controls and hypertriglyceridemic patients.</p
<p>Legend: <sup>§</sup>The values of mean±SD are listed;</p>*<p>Comparison with respective controls;...
*<p>Comparison with respective controls;</p>**<p>Comparison between type 1 and type 2 patients.</p>§...
Clinical characteristics of DM1 and DM2 patients and controls at baseline (T1) and follow-up (T2).</...
<p>Data are presented as mean (±SD), unless otherwise stated. Non-parametric data have been log tran...
<p>Results are expressed as Median (interquartile range).</p><p><sup>a</sup>comparison between CT an...
<p>The results are expressed as means ± SD. Abbreviations: BMI, body mass index; TG, triacylglycerol...
<p>Abbreviations: CI, confidence interval, hazard ratio.</p><p><sup>†</sup>p< 0.05,</p><p><sup>‡</su...
<p>Clinical and biochemical parameters for the healthy, WDM-NP, DM-WNP, and DM-NP subjects.</p
<p>All values are fasting values for KPDM and T1DM and are expressed as mean ± SD, where significanc...
<p>*<i>P</i><0.05</p><p>**<i>P</i><0.01 compared with healthy control</p><p>Demographic and Clinical...
<p>(A), the comparison of profiles of FGF21 between T2DM and NC. Black squares represent T2DM patien...
<p>Continuous variables are presented as means ± SD; categorical variables are presented as numbers;...
<p>(a) Heat-map of fold change of 33 differential metabolites; (b) Discrimination T2DM from DACD in ...
<p>Values are mean ± SEM.</p><p>n. a., not assessed.</p>*<p>p<0.05 baseline IT vs. 10th day of IT,</...
<p>Clinical and biochemical characteristics of controls and hypertriglyceridemic patients.</p
<p>Legend: <sup>§</sup>The values of mean±SD are listed;</p>*<p>Comparison with respective controls;...
*<p>Comparison with respective controls;</p>**<p>Comparison between type 1 and type 2 patients.</p>§...
Clinical characteristics of DM1 and DM2 patients and controls at baseline (T1) and follow-up (T2).</...
<p>Data are presented as mean (±SD), unless otherwise stated. Non-parametric data have been log tran...
<p>Results are expressed as Median (interquartile range).</p><p><sup>a</sup>comparison between CT an...
<p>The results are expressed as means ± SD. Abbreviations: BMI, body mass index; TG, triacylglycerol...
<p>Abbreviations: CI, confidence interval, hazard ratio.</p><p><sup>†</sup>p< 0.05,</p><p><sup>‡</su...
<p>Clinical and biochemical parameters for the healthy, WDM-NP, DM-WNP, and DM-NP subjects.</p
<p>All values are fasting values for KPDM and T1DM and are expressed as mean ± SD, where significanc...
<p>*<i>P</i><0.05</p><p>**<i>P</i><0.01 compared with healthy control</p><p>Demographic and Clinical...
<p>(A), the comparison of profiles of FGF21 between T2DM and NC. Black squares represent T2DM patien...
<p>Continuous variables are presented as means ± SD; categorical variables are presented as numbers;...
<p>(a) Heat-map of fold change of 33 differential metabolites; (b) Discrimination T2DM from DACD in ...
<p>Values are mean ± SEM.</p><p>n. a., not assessed.</p>*<p>p<0.05 baseline IT vs. 10th day of IT,</...
<p>Clinical and biochemical characteristics of controls and hypertriglyceridemic patients.</p